Human Papillomavirus (HPV)
Human Papillomavirus (HPV) is a group of more than 200 related viruses, some of which are sexually transmitted. It is one of the most common infections in the world, especially among sexually active people. Most HPV infections cause no symptoms and go away on their own, but some types can lead to serious health problems.
High-risk HPV types, especially HPV 16 and 18, can cause cervical cancer, as well as cancers of the anus, penis, throat, and vagina. Low-risk types like HPV 6 and 11 can cause genital warts but are not linked to cancer. HPV spreads mainly through skin-to-skin contact during vaginal, anal, or oral sex with someone who has the virus.
You can have HPV without knowing it, and you can pass it to others even if you have no signs or symptoms. There is no cure for HPV itself, but many of the health problems it causes are preventable or treatable. Vaccines like Gardasil protect against the most dangerous types of HPV and are most effective when given before sexual activity begins. Regular screening (like Pap smears and HPV tests) helps detect problems early, especially in women, and can prevent cervical cancer.
. HPV in Africa 🌍
- In Nairobi’s family planning clinics, 44% of women carried HPV, with multiple types common—HPV-52, 16, 35, and 66 were most frequent.
- Among WLWH, hr‑HPV infections are even more common, higher persistence, and associated with cervical dysplasia.
- Female sex workers showed baseline hr‑HPV prevalence ~20%; HIV-positive status raised hr‑HPV to ~32%.
- National screening is low: A full 85% know about cervical cancer, but only ~19% have ever been screened.
- Community-based self-collected HPV testing in health campaigns showed promise: ~36% screening uptake; 19% tested hr‑HPV positive.
- HPV vaccination drives (age 10–14) in public schools are ongoing, though accurate coverage data remains limited.
- Persistent hr‑HPV during pregnancy/lactation is high (~84%), with over half remaining infected post-delivery.
- No direct link with preterm birth, but persistent high-risk HPV correlates with vertical HIV transmission to infants.
- HPV can be transmitted mother-to-child, though most neonatal infections are asymptomatic; infant immune status matters.
- Routine immunisation: Kenya currently offers HPV vaccines (Cervarix, Gardasil) through schools and public health centers (
- Catch-up campaigns: Modeling shows expanding catch-up coverage to older adolescents and young women dramatically reduces cervical cancer burden, especially where HIV is prevalent.
- Integrated self-collection HPV testing: In western Kenya, community-based self-sampling during multi-disease campaigns shows increased acceptability and reach.
- Stigma reduction: Studies recommend patient-centered care, peer outreach, and ensuring confidentiality to combat stigma.
- Kenya hosts numerous studies mapping HPV type distribution, co-infections (HIV, Chlamydia), CIN risk, contraceptive interactions with HPV.
- Pilot initiatives like genomic HPV testing (noted in Reddit discussions) are being explored to identify high-risk individuals earlier.
- Expand catch-up campaigns (age 9–26), aligning with WHO recommendations to plug current vaccination gaps.
- Deploy community-based peer education, leveraging trusted local figures to reduce myths and logistical barriers.
- Offer self-collection kits at community health days (e.g., HIV/TB outreach) to bypass stigma and reach underserved women.
- Strengthen integrated screening in maternal health clinics, so pregnant women are screened for HPV/CIN during routine ANC visits.
- Monitor HPV in pregnancy: Track HPV during pregnancy to understand outcomes like persistence and effects on HIV transmission.
- Link screening with postpartum follow-up: Ensure women with positive HPV tests get follow-up post-delivery to close care gaps.
- National registry & surveillance: Track vaccination, screening, and treatment across regions.
- Train providers on stigma-awareness, confidentiality, and empathetic communication to improve trust.
- Ensure sustainable financing: Through government budgets, Gavi, and partners.
- Evaluate effectiveness of different vaccines (bivalent/trivalent vs. nonavalent) across regional HPV types.
- Study vaccine impact on HIV acquisition and transmission, given emerging evidence of HPV’s role.
- Conduct longitudinal maternal–child health studies on HPV effects and outcomes, including infant infection and immune response.
HPV remains a top public health concern—especially for WLWH and pregnant women in Kenya. But with integrated strategies—expanding vaccination, scaled-up screening (including self-sampling), maternal-focused care, stigma reduction, and robust research—Kenya can drive toward cervical cancer elimination and improve maternal health outcomes.